EUVIMEDEUVIMED entdecken
Open Access

Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma

Yao Yu iD, Xufen Yu iD, Bo Pan iD, Ho Man Chan iD, H Ümit Kaniskan iD, Jian Jin iD, Ling Cai iD, Gang Greg Wang iD

Science Advances · 25.04.2025 · 11 (17)

DOI: 10.1126/sciadv.ads7876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 25.04.2025. Verfasst von Yao Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA. Hauptthemen laut MEDLINE: Sarcoma, Synovial, Proteolysis, Histone-Lysine N-Methyltransferase, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-causing aberrations recurrently target the chromatic-regulatory factors, leading to epigenetic dysregulation. Almost all patients with synovial sarcoma (SS) carry a characteristic gene fusion, SS18::SSX, which produces a disease-specific oncoprotein that is incorporated into the switch/sucrose non-fermentable (SWI/SNF) chromatin-remodeling complexes and profoundly alters their functionalities. Targeting epigenetic dependency in cancers holds promise for improving current treatment. Leveraging on cancer cell dependency dataset, pharmacological tools, and genomic profiling, we find WDR5, a factor critical for depositing histone H3 lysine 4 (H3K4) methylation, to be an unexplored vulnerability in SS. Mechanistically, WDR5 and SS18::SSX interact and colocalize at oncogenes where WDR5 promotes H3K4 methylation and the chromatin association of SS18::SSX-containing chromatin-remodeling complexes. WDR5 degradation by proteolysis-targeting chimera (PROTAC) not only suppresses the SS18::SSX-related oncogenic programs but additionally causes the ribosomal protein deregulations leading to p53 activation. WDR5-targeted PROTAC suppresses SS growth in vitro and in vivo, providing a promising strategy for the SS treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, SynovialProteolysisHistone-Lysine N-MethyltransferaseOncogene Proteins, FusionIntracellular Signaling Peptides and ProteinsHumansAnimalsCell Line, TumorMiceHistonesGene Expression Regulation, NeoplasticMethylationCell ProliferationXenograft Model Antitumor Assays

Substanzen

WDR5 protein, humanHistone-Lysine N-MethyltransferaseOncogene Proteins, FusionSS18-SSX1 fusion proteinHistonesIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA 02451, USA.
  • Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA.

ORCID-Profile: Yao Yu, Xufen Yu, Bo Pan, Ho Man Chan, H Ümit Kaniskan, Jian Jin, Ling Cai, Gang Greg Wang

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NCRR NIH HHS

Zitieren

APA

Yu, Y., Yu, X., Pan, B., Chan, H. M., Kaniskan, H. Ü., Jin, J., Cai, L., & Wang, G. G. (2025). Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma. Science Advances, 11(17). https://doi.org/10.1126/sciadv.ads7876

Vancouver

Yu Y, Yu X, Pan B, Chan HM, Kaniskan HÜ, Jin J, et al. Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma. Science Advances. 2025;11(17). doi:10.1126/sciadv.ads7876

BibTeX
@article{Yu2025,
  author = {Yu, Yao and Yu, Xufen and Pan, Bo and Chan, Ho Man and Kaniskan, H Ümit and Jin, Jian and Cai, Ling and Wang, Gang Greg},
  title = {Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {17},
  doi = {10.1126/sciadv.ads7876}
}
Kostenlos starten →